Page last updated: 2024-12-08
beta-naphthamidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
beta-naphthamidine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 193409 |
| CHEMBL ID | 105171 |
| SCHEMBL ID | 3370031 |
| MeSH ID | M0070314 |
Synonyms (20)
| Synonym |
|---|
| 5651-14-9 |
| beta-naphthamidine |
| bdbm50138663 |
| upa_6 |
| 2-naphthimidamide |
| naphthalene-2-carboxamidine |
| CHEMBL105171 , |
| 2-naphthalenecarboximidamide |
| SCHEMBL3370031 |
| naphthalene-2-carboximidamide |
| 2up , |
| AKOS009312986 |
| URXJHZXEUUFNKM-UHFFFAOYSA-N |
| DTXSID40205052 |
| 2-naphthamidine |
| FT-0763708 |
| Q27453295 |
| AT29325 |
| EN300-215001 |
| Z381356458 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " These compounds possess excellent binding activities and selectivities with significantly improved pharmacokinetic profiles versus previously described amide-linked inhibitors." | ( Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. Bouska, J; Bruncko, M; Dalton, CR; Dellaria, JF; Geyer, A; Giranda, VL; Gong, J; Kaminski, MA; Klinghofer, V; Mantei, R; McClellan, WJ; Nienaber, VL; Rockway, TW; Sauer, DR; Stewart, K; Weitzberg, M; Wendt, MD; Zhao, X, 2005) | 0.33 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (6)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Plasminogen | Homo sapiens (human) | Ki | 51.1500 | 0.0170 | 1.1560 | 4.4000 | AID157977; AID158340 |
| Urokinase-type plasminogen activator | Homo sapiens (human) | Ki | 6.0399 | 0.0170 | 2.6268 | 7.0000 | AID213441; AID215835; AID419413 |
| Tissue-type plasminogen activator | Homo sapiens (human) | Ki | 100.0000 | 0.0170 | 3.7196 | 8.6000 | AID210752; AID210919 |
| Kallikrein-1 | Homo sapiens (human) | Ki | 23.0000 | 0.0610 | 0.4157 | 0.6100 | AID150768 |
| Trypsin-1 | Homo sapiens (human) | Ki | 7.7900 | 0.0000 | 1.7676 | 8.9000 | AID215587; AID215747 |
| Thromboxane-A synthase | Rattus norvegicus (Norway rat) | Ki | 7.8000 | 7.8000 | 7.8000 | 7.8000 | AID215747 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (43)
Molecular Functions (14)
Ceullar Components (21)
Bioassays (11)
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.85
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.85) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||